使用直接作用抗病毒药物 (DAAs) 根治慢性丙型肝炎后肝硬化患者的长期疗效。

IF 4.2 3区 医学 Q2 ONCOLOGY Journal of Hepatocellular Carcinoma Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI:10.2147/JHC.S475810
Mohsen Salama, Nehad Darwesh, Maha Mohammad Elsabaawy, Eman Abdelsameea, Asmaa Gomaa, Aliaa Sabry
{"title":"使用直接作用抗病毒药物 (DAAs) 根治慢性丙型肝炎后肝硬化患者的长期疗效。","authors":"Mohsen Salama, Nehad Darwesh, Maha Mohammad Elsabaawy, Eman Abdelsameea, Asmaa Gomaa, Aliaa Sabry","doi":"10.2147/JHC.S475810","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens.</p><p><strong>Patients and methods: </strong>This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up.</p><p><strong>Results: </strong>About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin (<i>P</i> = 0.001), liver enzymes (<i>P</i> = 0.001), alpha-fetoprotein (AFP) (<i>P</i> < 0.001), platelet count (<i>P</i> = 0.001), the model for end-stage liver disease (MELD) score (<i>P</i> = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores (<i>p</i> < 0.001). The liver stiffness (LS) also significantly improved (<i>p</i> = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation (<i>p</i> = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development.</p><p><strong>Conclusion: </strong>Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531736/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs).\",\"authors\":\"Mohsen Salama, Nehad Darwesh, Maha Mohammad Elsabaawy, Eman Abdelsameea, Asmaa Gomaa, Aliaa Sabry\",\"doi\":\"10.2147/JHC.S475810\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens.</p><p><strong>Patients and methods: </strong>This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up.</p><p><strong>Results: </strong>About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin (<i>P</i> = 0.001), liver enzymes (<i>P</i> = 0.001), alpha-fetoprotein (AFP) (<i>P</i> < 0.001), platelet count (<i>P</i> = 0.001), the model for end-stage liver disease (MELD) score (<i>P</i> = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores (<i>p</i> < 0.001). The liver stiffness (LS) also significantly improved (<i>p</i> = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation (<i>p</i> = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development.</p><p><strong>Conclusion: </strong>Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis.</p>\",\"PeriodicalId\":15906,\"journal\":{\"name\":\"Journal of Hepatocellular Carcinoma\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531736/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatocellular Carcinoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/JHC.S475810\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S475810","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在确定肝硬化患者在接受基于直接作用抗病毒药物(DAAs)的治疗方案后获得持续病毒学应答(SVR)的长期疗效:这项研究涉及193名HCV相关肝硬化患者,他们都曾完成DAAs治疗并获得SVR。分析了治疗结束后第一年和第三年随访的临床、实验室和放射学特征。在5年随访中确定了总生存期(OS)和肝功能失代偿或肝细胞癌(HCC)的发生率:结果:约68.4%的HCV相关性肝硬化患者为男性,平均年龄为(54.8 ± 7.7)岁。第一年和第三年的随访结果显示,白蛋白(P = 0.001)、肝酶(P = 0.001)、甲胎蛋白(AFP)(P < 0.001)、血小板计数(P = 0.001)、终末期肝病模型(MELD)评分(P = 0.001 和 0.01)、FIB4 和天冬氨酸氨基转移酶与血小板比值指数(APRI)评分(P < 0.001)均有显著改善。肝脏僵硬度(LS)也有明显改善(p = 0.001)。第5年的平均OS为58.3个月,分别有14.5%和17.6%的患者出现新发HCC和失代偿。发生HCC和肝功能失代偿的患者第5年随访的平均OS较短(P = 0.001)。甲胎蛋白和LS是HCC发生的预测因素:结论:尽管获得了 SVR,肝硬化患者仍需持续监测 HCC 和新出现的失代偿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs).

Purpose: This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens.

Patients and methods: This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up.

Results: About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin (P = 0.001), liver enzymes (P = 0.001), alpha-fetoprotein (AFP) (P < 0.001), platelet count (P = 0.001), the model for end-stage liver disease (MELD) score (P = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores (p < 0.001). The liver stiffness (LS) also significantly improved (p = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation (p = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development.

Conclusion: Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
期刊最新文献
Circulating Biomarkers Predict Immunotherapeutic Response in Hepatocellular Carcinoma Using a Machine Learning Method. Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs). A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection. FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study. Gamma-Glutamyl Transpeptidase to Neutrophil Ratio as Prognostic Indicator for Hepatocellular Carcinoma Patients Post-Curative Resection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1